Listernick R, Charrow J, Gutmann D H
Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Am J Med Genet. 1999 Mar 26;89(1):38-44. doi: 10.1002/(sici)1096-8628(19990326)89:1<38::aid-ajmg8>3.0.co;2-m.
Optic pathway gliomas and brainstem gliomas are the predominant intracranial neoplasms associated with neurofibromatosis type 1 (NF1). Before the past 15 years, studies of optic pathway gliomas in NF1 were hampered by the inaccurate diagnosis of NF1, the unavailability of noninvasive neuroimaging techniques, and the frequent rendering of what would now be considered unnecessary, overly aggressive therapy. When studied systematically, these tumors behave in a much more benign fashion than their counterparts in children who do not have NF1. While they may cause symptoms in as many of 50% of cases, progression to the point where specific intervention is deemed necessary is unusual. Consequently, screening neuroimaging of asymptomatic patients is unwarranted. Because optic pathway tumors universally arise in children younger than 7 years of age, all such children should undergo yearly ophthalmologic evaluations and annual assessments of growth to monitor for signs of precocious puberty. Am. J. Med. Genet. (Semin. Med. Genet.) 89:38-44, 1999.
视路胶质瘤和脑干胶质瘤是与1型神经纤维瘤病(NF1)相关的主要颅内肿瘤。在过去15年之前,NF1视路胶质瘤的研究受到NF1诊断不准确、无创神经成像技术不可用以及频繁进行现在认为不必要的过度积极治疗的阻碍。当进行系统研究时,这些肿瘤的行为比没有NF1的儿童中的同类肿瘤更为良性。虽然它们在多达50%的病例中可能引起症状,但进展到需要进行特定干预的程度并不常见。因此,对无症状患者进行筛查性神经成像没有必要。由于视路肿瘤普遍发生在7岁以下的儿童中,所有此类儿童都应每年接受眼科评估和生长年度评估,以监测性早熟迹象。《美国医学遗传学杂志》(医学遗传学研讨会)89:38 - 44,1999年。